IMAGE

Fig. 2

ID
ZDB-IMAGE-170609-34
Genes
Source
Figures for Theodore et al., 2017
Image
Figure Caption

Fig. 2

Inhibition of Mmp2, but Not Mmp9, Function Affects EHT in the VDA

(A) Exposure to prinomastat (20 μM) or ARP-101 (10 μM; 12–36 hpf) caused abnormal runx1/cmyb patterning in the VDA, while MMP9-I (5 μM) had no effect.

(B) Qualitative phenotypic distribution of embryos from (A) scored with normal or abnormal runx1/cmyb expression (n ≥ 20/condition).

(C) In vivo imaging of Flk1:GFP at 36 hpf indicated that MMP inhibitor (12–36 hpf) treatment did not affect physical vasculature structure (n ≥ 5 embryos/condition).

(D) FACS analysis of double-positive HSPCs in Tg(kdrl:dsred/cmyb:gfp) embryos showed no difference in HSPCs after MMP inhibitor exposure (12–36 hpf; 5 embryos/sample, ≥3 replicates/condition).

(E) MO knockdown of mmp2 or mmp9 phenocopied effects of chemical inhibition on runx1/cmyb WISH at 36 hpf.

(F) Phenotypic distribution of embryos from (E) scored for runx1/cmyb expression (as in A) in the AGM (n value as in B).

(G) MO knockdown of mmp2 or mmp9 had no impact on Flk1:GFP+ endothelium (n value as in C).

(H) FACS analysis of Flk1:dsRed+/cMyb:GFP+ HSPCs showed no significant difference between mmp2 or mmp9 morphants and controls at 36 hpf (n value as in D).

Arrowheads mark HSPC clusters. Error bars denote mean ± SD. Scale bars, 100 μm.

Figure Data
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Stem Cell Reports